Presented by: Gunjan Junnarkar, Ph.D, VP Pharmaceutical Development, Jazz Pharmaceuticals
Dr. Junnarkar is a Pharmaceutical Scientist with over 25 years of experience in pharmaceutical product development, drug delivery systems, and drug-device combination products. She has provided scientific, technical, and strategic leadership to advance therapeutic agents from research to regulatory approval. Demonstrated skills in formulation design and development, manufacturing process development, and regulatory submissions. Published author of literature articles and holder of patents in Pharmaceutical Sciences. Gunjan is the Vice President of Pharmaceutical Development at Jazz Pharmaceuticals with a history of roles at Jazz Pharmaceuticals, Johnson & Johnson, and SRI International.
Thursday, October 17, 2024
11:00am – 12:00pm Central Time
Webinar held via zoom
Overview: The treatment of narcolepsy and idiopathic hypersomnia has seen significant advancements with the development of a low-sodium oxybate formulation. This innovative approach addresses the cardiovascular risks associated with high sodium intake, providing a safer alternative for long-term management of these sleep disorders. In this session, we will explore the formulation process, clinical trials, and the implications of low-sodium oxybate for patient care in narcolepsy and idiopathic hypersomnia.
This opportunity is made possible by the Sleep Research Society Foundation.
